Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis
Conditions
- Relapsing-Remitting Multiple Sclerosis
Interventions
- BIOLOGICAL: BIIB019 (Daclizumab High Yield Process)
- DRUG: Interferon beta-1a Placebo
- BIOLOGICAL: Interferon beta-1a
- DRUG: Daclizumab High Yield Process Placebo
Sponsor
Biogen
Collaborators